Companies · Other Health Care

Direct Flow Medical, Inc.

SANTA ROSA · Other Health Care

Diligence memoA one-page analyst read on Direct Flow Medical, Inc. — recommendation, valuation, rhythm, risks.
$170.5M
Total raised · real
6
Rounds
0.6×
Latest step-up
Top 3%
Sector rank · raised
Series C
Latest stage · inferred · Wed Mar 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time)

Direct Flow Medical, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.60× the median modeled value of Series C Other Health Care companies in 2016–2018 (40 peers) — value vs value, same stage and era.
Dormant
  • Last raise 10.3 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Direct Flow Medical, Inc. is one of 5377 Other Health Care companies tracked from SANTA ROSA. By capital raised it ranks among the largest (ahead of 98% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries C · 2009-09-18 Raised $40M (real) Modeled valuation $921M (est)$40M$921MSeries C2009Series B · 2009-09-18 Raised $40M (real) Modeled valuation $886M (est)$40M$886MSeries B2009Series C · 2014-09-12 Raised $17M (real) Modeled valuation $390M (est)$17M$390MSeries C2014Series C · 2014-09-12 Raised $31M (real) Modeled valuation $708M (est)$31M$708MSeries C2014Series C · 2016-03-16 Raised $27M (real) Modeled valuation $620M (est)$27M$620MSeries C2016Series C · 2016-03-16 Raised $15M (real) Modeled valuation $345M (est)$15M$345MSeries C2016+$40M+$17M+$31M+$27M+$15MCumulative $171M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series C$40.3M · 2009
Bridge · Series C-stage$40.0M · 2009smaller follow-on
Series C extension$17.1M · 2014
Series C extension$31.0M · 2014
Series C extension$27.1M · 2016
Series C extension$15.1M · 2016

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 40%.

Modeled valuation trajectory
$619.6M
Base estimate est.
$98.5M
Conservative case
$1.6B
Upside case
$180.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series C · modeled $921.0M · 2009-09-182009Series B · modeled $886.2M · 2009-09-18Series C · modeled $390.1M · 2014-09-12Series C · modeled $708.4M · 2014-09-12Series C · modeled $619.6M · 2016-03-16Series C · modeled $344.8M · 2016-03-162016
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
73%
Survival probability
55% low · 85% high
1.29×/yr
Annual markup
1.48×/yr upside case
6.0 yr
Elapsed time used
10.3 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$26.3M/yr
Capital velocity
16.8 yr
On record since
2009
First round
6
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 70× above median
This company$170.5M
Sector median$2.4M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.3× of median
This company$15.1M
Sector median$45.9M
Modeled value — vs sector median (estimate, all stages) 28× above median
This company$619.6M
Sector median$22.1M

Raised more than 98% of sector peers (real $). Modeled value above 94% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #31 of 40.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Specialty Networks, LLC · Series C Raised $94.5M · modeled $2.2B (est)New MMI Holdings, Inc. · Series C Raised $80.7M · modeled $1.8B (est)BioMatrix Holdings, L.L.C. · Series C Raised $80.0M · modeled $1.8B (est)Sea Hunter Holdings, LLC · Series C Raised $76.3M · modeled $1.7B (est)Bind Benefits, Inc. · Series C Raised $70.0M · modeled $1.6B (est)Endotronix Inc · Series C Raised $116.1M · modeled $1.6B (est)Great Basin Scientific, Inc. · Series C Raised $124.3M · modeled $1.6B (est)TransMedics, Inc. · Series C Raised $249.0M · modeled $1.5B (est)Landmark Health, LLC · Series C Raised $90.8M · modeled $1.4B (est)Rapid Micro Biosystems, Inc. · Series C Raised $134.6M · modeled $1.4B (est)Mdp Acm Holdings, Llc · Series C Raised $60.0M · modeled $1.4B (est)ACON BioMatrix Investors I, L.L.C. · Series C Raised $57.5M · modeled $1.3B (est)Direct Flow Medical, Inc. (this company) Raised $170.5M · modeled $619.6M (est)Direct Flow Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
Specialty Networks, LLCSeries C$94.5M$2.2B2.08×
New MMI Holdings, Inc.Series C$80.7M$1.8B1.77×
BioMatrix Holdings, L.L.C.Series C$80.0M$1.8B1.76×
Sea Hunter Holdings, LLCSeries C$76.3M$1.7B1.68×
Bind Benefits, Inc.Series C$70.0M$1.6B1.54×
Endotronix IncSeries C$116.1M$1.6B1.52×
Great Basin Scientific, Inc.Series C$124.3M$1.6B1.49×
TransMedics, Inc.Series C$249.0M$1.5B1.40×
Landmark Health, LLCSeries C$90.8M$1.4B1.34×
Rapid Micro Biosystems, Inc.Series C$134.6M$1.4B1.32×
Mdp Acm Holdings, LlcSeries C$60.0M$1.4B1.32×
ACON BioMatrix Investors I, L.L.C.Series C$57.5M$1.3B1.26×
Direct Flow Medical, Inc. this companySeries C$170.5M$619.6M0.60×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series C$40.3M2009-09-18$268.6M$921.0M90%
Series B$40.0M2009-09-18$222.2M$886.2M90%
Series C$17.1M2014-09-12$113.8M$390.1M90%
Series C$31.0M2014-09-12$206.6M$708.4M90%
Series C$27.1M2016-03-16$180.7M$619.6M90%
Series C$15.1M2016-03-16$100.5M$344.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series C$40.3M2009-09-18
    • First recorded raise — entered as Series C.
  2. Series B$40.0M2009-09-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
  3. Series C$17.1M2014-09-12
    • Raised again after 60 mo — slower than the ~14 mo sector norm.
    • Round 2.3× smaller than the prior — bridge or down round.
  4. Series C$31.0M2014-09-12
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× larger than the prior — scaling up.
  5. Series C$27.1M2016-03-16
    • Raised 18 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  6. Series C$15.1M2016-03-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
Intelligence
2017 ~Q3
Modeled next raise · ~16mo cadence
$15.1M
Modeled next size est.range $15.1M$24.1M
0.6×
Last step-up
$26.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
PAUL LAVIOLETTE11 other2009-09
Jeani Delagardelle7 other2009-09
Michael DeVries7 other2009-09
J. Daniel Cole6 other2009-09
Lee Wrubel4 other2009-09
Mark Weeks3 other2009-09
Bernard Lyons2 other2009-09
Scott Moonly2 other2009-09
Jay Shukert1 other2009-09
Bernard E. Lyons2009-09
Brian E. Sheahan2009-09
Brian Sheahan2009-09
Charles J. Davidson2014-09
Chris T. Richardson2014-09
Dan R. Rose2014-09
Dan T. Lemaitre2014-09
Dan T. Rose2014-09
David R. Elizondo2009-09
David T. Boyle2014-09
George T. Fazio2014-09
Gordon Bishop2009-09
Gordon E. Bishop2009-09
Gordon T. Bishop2014-09
Greg T. Madden2014-09
Registry & provenance

Direct Flow Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1296743
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Endogastric Solutions IncOther Health CareSeries C$177.3M$557.6Mnetwork1 shared operator · same sector · same stage
Conventus Orthopaedics IncOther Health CareSeries C$144.2M$921.2Mnetwork1 shared operator · same sector · same stage
Endotronix IncOther Health CareSeries C$116.1M$1.6Bnetwork1 shared operator · same sector · same stage
Cardiokinetix IncOther Health CareSeries B$55.3M$680.3Mnetwork2 shared operators · same sector
Intrapace IncOther Health CareSeries D+$179.1M$76.8Mnetwork1 shared operator · same sector
Exo Imaging, Inc.Other Health CareSeries C$169.6M$284.6Msame sector · same stage
Precision Neuroscience CorpOther Health CareSeries C$172.3M$713.2Msame sector · same stage
ExploraMed NC7, Inc.Other Health CareSeries C$181.5M$752.1Msame sector · same stage
Frequently asked
How much funding has Direct Flow Medical, Inc. raised?
Direct Flow Medical, Inc. has raised approximately $170.5M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Direct Flow Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Direct Flow Medical, Inc. is approximately $619.6M (modeled range $98.5M–$1.6B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Direct Flow Medical, Inc. at?
Direct Flow Medical, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Wed Mar 16.
What does Direct Flow Medical, Inc. do and where is it based?
Direct Flow Medical, Inc. operates in the Other Health Care sector, based in SANTA ROSA.
Explore related

See where Direct Flow Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Direct Flow Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.